Shuai Ren

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9528251/publications.pdf

Version: 2024-02-01

840119 839053 32 399 11 18 citations h-index g-index papers 34 34 34 492 citing authors docs citations times ranked all docs

#	Article	lF	CITATIONS
1	<p>Pancreatic neuroendocrine tumor: prediction of the tumor grade using magnetic resonance imaging findings and texture analysis with 3-T magnetic resonance</p> . Cancer Management and Research, 2019, Volume 11, 1933-1944.	0.9	39
2	Evaluation of Texture Analysis for the Differential Diagnosis of Mass-Forming Pancreatitis From Pancreatic Ductal Adenocarcinoma on Contrast-Enhanced CT Images. Frontiers in Oncology, 2019, 9, 1171.	1.3	28
3	Emodin suppresses cadmium-induced osteoporosis by inhibiting osteoclast formation. Environmental Toxicology and Pharmacology, 2017, 54, 162-168.	2.0	27
4	The Binary System of Ibuprofen-Nicotinamide Under Nanoscale Confinement: From Cocrystal to Coamorphous State. Journal of Pharmaceutical Sciences, 2017, 106, 3150-3155.	1.6	26
5	<p>Pancreatic Ductal Adenocarcinoma: Machine Learning–Based Quantitative Computed Tomography Texture Analysis For Prediction Of Histopathological Grade</p> . Cancer Management and Research, 2019, Volume 11, 9253-9264.	0.9	25
6	Diagnostic accuracy of unenhanced CT texture analysis to differentiate mass-forming pancreatitis from pancreatic ductal adenocarcinoma. Abdominal Radiology, 2020, 45, 1524-1533.	1.0	25
7	Berberine exerts anti-tumor activity in diffuse large B-cell lymphoma by modulating c-myc/CD47 axis. Biochemical Pharmacology, 2021, 188, 114576.	2.0	23
8	Computed Tomography-Based Radiomics Signature for the Preoperative Differentiation of Pancreatic Adenosquamous Carcinoma From Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology, 2020, 10, 1618.	1.3	20
9	Differentiation of hypovascular pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography. PLoS ONE, 2019, 14, e0211566.	1.1	19
10	Differentiation Between G1 and G2/G3 Phyllodes Tumors of Breast Using Mammography and Mammographic Texture Analysis. Frontiers in Oncology, 2019, 9, 433.	1.3	19
11	<p>Differentiation of chronic mass-forming pancreatitis from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography</p> . Cancer Management and Research, 2019, Volume 11, 7857-7866.	0.9	17
12	A GPC1-targeted and gemcitabine-loaded biocompatible nanoplatform for pancreatic cancer multimodal imaging and therapy. Nanomedicine, 2019, 14, 2339-2353.	1.7	15
13	Emodin-Conjugated PEGylation of Fe3O4 Nanoparticles for FI/MRI Dual-Modal Imaging and Therapy in Pancreatic Cancer. International Journal of Nanomedicine, 2021, Volume 16, 7463-7478.	3.3	12
14	CT and MR imaging features of pancreatic adenosquamous carcinoma and their correlation with prognosis. Abdominal Radiology, 2019, 44, 2822-2834.	1.0	11
15	Imaging findings of intraductal tubulopapillary neoplasm (ITPN) of the pancreas. Medicine (United) Tj ETQq $1\ 1$	0.784314	rgBT1/Overlack
16	Exogenous HMGB1 Promotes the Proliferation and Metastasis of Pancreatic Cancer Cells. Frontiers in Medicine, 2021, 8, 756988.	1.2	11
17	Preoperative differentiation of serous cystic neoplasms from mucin-producing pancreatic cystic neoplasms using a CT-based radiomics nomogram. Abdominal Radiology, 2021, 46, 2637-2646.	1.0	10
18	Differentiating hypovascular pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinoma based on CT texture analysis. Acta Radiologica, 2020, 61, 595-604.	0.5	9

#	Article	IF	Citations
19	Differentiation of aggressive from non-aggressive pancreatic solid pseudopapillary neoplasms using computed tomography. Abdominal Radiology, 2019, 44, 2448-2458.	1.0	8
20	The value of the apparent diffusion coefficient in differentiating type II from type I endometrial carcinoma. Acta Radiologica, 2021, 62, 959-965.	0.5	8
21	Differentiation of duodenal gastrointestinal stromal tumors from hypervascular pancreatic neuroendocrine tumors in the pancreatic head using contrast-enhanced computed tomography. Abdominal Radiology, 2019, 44, 867-876.	1.0	7
22	Evaluation of contrast-enhanced computed tomography for the differential diagnosis of hypovascular pancreatic neuroendocrine tumors from chronic mass-forming pancreatitis. European Journal of Radiology, 2020, 133, 109360.	1.2	7
23	DifferentiationÂbetweenÂrenal oncocytomasÂandÂchromophobe renal cell carcinomasÂusingÂdynamicÂcontrast-enhancedÂcomputedÂtomography. Abdominal Radiology, 2021, 46, 3309-3316.	1.0	5
24	Potential Metabolite Biomarkers for Early Detection of Stage-I Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology, 2021, 11, 744667.	1.3	5
25	Qian Yang Yu Yin Granule Improves Renal Injury of Hypertension by Regulating Metabolic Reprogramming Mediated by HIF-1α/PKM2 Positive Feedback Loop. Frontiers in Pharmacology, 2021, 12, 667433.	1.6	4
26	Combined therapy of hypertensive nephropathy with ginkgo leaf extract and dipyridamole injection and antihypertensive drugs. Medicine (United States), 2021, 100, e25852.	0.4	3
27	Carcinoid Tumorlets Co-Existing with Chronic Pulmonary Inflammatory Processes: Imaging Findings and Histological Appearances. Medical Science Monitor, 2020, 26, e926014.	0.5	2
28	Application of Unenhanced Computed Tomography Texture Analysis to Differentiate Pancreatic Adenosquamous Carcinoma from Pancreatic Ductal Adenocarcinoma. Current Medical Science, 2022, 42, 217-225.	0.7	2
29	Letter regarding "Nonhypervascular pancreatic neuroendocrine tumors: Spectrum of MDCT imaging findings and differentiation from pancreatic ductal adenocarcinoma― European Journal of Radiology, 2020, 132, 109282.	1.2	O
30	Letter regarding "Complementary role of computed tomography texture analysis for differentiation of pancreatic ductal adenocarcinoma from pancreatic neuroendocrine tumors in the portal-venous enhancement phase― Abdominal Radiology, 2021, 46, 1648-1649.	1.0	0
31	Carcinoid Tumorlets Co-Existing with Chronic Pulmonary Inflammatory Processes: Imaging Findings and Histological Appearances. Medical Science Monitor, 2020, 26, e926014.	0.5	O
32	Can Relative Enhancement Ratio of Portal Venous Phase to Unenhanced CT Be Used to Differentiate Lipid-Poor Adrenal Adenomas from Adrenal Hyperplasia?. Radiology, 2022, , 212331.	3.6	O